» Articles » PMID: 11410123

A Conditional Form of Bruton's Tyrosine Kinase is Sufficient to Activate Multiple Downstream Signaling Pathways Via PLC Gamma 2 in B Cells

Overview
Journal BMC Immunol
Publisher Biomed Central
Date 2001 Jun 21
PMID 11410123
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bruton's tyrosine kinase (Btk) is essential for B cell development and function. Mutations of Btk elicit X-linked agammaglobulinemia in humans and X-linked immunodeficiency in the mouse. Btk has been proposed to participate in B cell antigen receptor-induced signaling events leading to activation of phospholipase C-gamma2 (PLCgamma2) and calcium mobilization. However it is unclear whether Btk activation is alone sufficient for these signaling events, and whether Btk can activate additional pathways that do not involve PLCgamma2. To address such issues we have generated Btk:ER, a conditionally active form of the kinase, and expressed it in the PLCgamma2-deficient DT40 B cell line.

Results: Activation of Btk:ER was sufficient to induce multiple B cell signaling pathways in PLCgamma2-sufficient DT40 cells. These included tyrosine phosphorylation of PLCgamma2, mobilization of intracellular calcium, activation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) pathways, and apoptosis. In DT40 B cells deficient for PLCgamma2, Btk:ER activation failed to induce the signaling events described above with the consequence that the cells failed to undergo apoptosis.

Conclusions: These data suggest that Btk:ER regulates downstream signaling pathways primarily via PLCgamma2 in B cells. While it is not known whether activated Btk:ER precisely mimics activated Btk, this conditional system will likely facilitate the dissection of the role of Btk and its family members in a variety of biological processes in many different cell types.

Citing Articles

Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story.

Moraru R, Valle-Argos B, Minton A, Buermann L, Pan S, Wales T J Med Chem. 2024; 67(16):13572-13593.

PMID: 39119945 PMC: 11345841. DOI: 10.1021/acs.jmedchem.3c01927.


Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.

Malarz K, Korzuch J, Marforio T, Balin K, Calvaresi M, Mrozek-Wilczkiewicz A Int J Nanomedicine. 2023; 18:1709-1724.

PMID: 37025922 PMC: 10072273. DOI: 10.2147/IJN.S403058.


Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.

Kroller S, Wissuwa B, Dennhardt S, Krieg N, Thiemermann C, Daniel C Front Immunol. 2023; 14:1105181.

PMID: 36911665 PMC: 9995712. DOI: 10.3389/fimmu.2023.1105181.


Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells.

Elbezanti W, Al-Odat O, Chitren R, Singh J, Srivastava S, Gowda K Front Pharmacol. 2022; 13:894535.

PMID: 36160379 PMC: 9500300. DOI: 10.3389/fphar.2022.894535.


The inositol 5-phosphatase INPP5B regulates B cell receptor clustering and signaling.

Droubi A, Wallis C, Anderson K, Rahman S, De Sa A, Rahman T J Cell Biol. 2022; 221(9).

PMID: 35878408 PMC: 9351708. DOI: 10.1083/jcb.202112018.


References
1.
Yang W, Desiderio S . BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci U S A. 1997; 94(2):604-9. PMC: 19560. DOI: 10.1073/pnas.94.2.604. View

2.
Dolmetsch R, Lewis R, Goodnow C, Healy J . Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature. 1997; 386(6627):855-8. DOI: 10.1038/386855a0. View

3.
Ishiai M, Kurosaki M, Pappu R, Okawa K, Ronko I, Fu C . BLNK required for coupling Syk to PLC gamma 2 and Rac1-JNK in B cells. Immunity. 1999; 10(1):117-25. DOI: 10.1016/s1074-7613(00)80012-6. View

4.
Jiang A, Craxton A, Kurosaki T, Clark E . Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med. 1998; 188(7):1297-306. PMC: 2212500. DOI: 10.1084/jem.188.7.1297. View

5.
Satterthwaite A, Witte O . The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000; 175:120-7. View